Statins × blood pressure

TrialThe lancet. HIV2026

Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trial.

Esteban Martínez et al.PubMed ↗Full text ↗Publisher ↗

  • Pitavastatinlooks good hereLower hypertension.Randomised, large.

What the trial testedrandomised · 7,769 people · 2026

Randomised vs placebo

Lowered hypertension

−17%−29% to −3%

pitavastatin vs placebo

Bigger than 4 in 10 on the map

As reported

HR 0.83, 95% CI 0.71–0.97 · the paper's word: incidence of hypertension

Who was studied, and how

7,769people with hypertension, in this paper

The trial randomly assignedassigned by chance

pitavastatin
placebo

Lowered hypertension−17%

randomised

the abstract, start to end

(cause-specific hazard ratio [HR] 0.83, 95% CI 0.71-0.97; p=0.017).

← favours treatmentfavours comparator →
could be chance
Incidence of hypertensionpitavastatin vs placebo
HR 0.830.71–0.97
StatinsBlood pressure

Statins × blood pressurehelps?replicated

unlikelylikely
0.830.80 without it
← favours comparatorfavours treatment →
more certainless certain
1 / 6

Not cited yet

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 42067280